RT Journal Article
SR Electronic
T1 Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.22.21249945
DO 10.1101/2021.01.22.21249945
A1 Sofie Bliddal
A1 Karina Banasik
A1 Ole Birger Pedersen
A1 Ioanna Nissen
A1 Lisa Cantwell
A1 Michael Schwinn
A1 Morten Tulstrup
A1 David Westergaard
A1 Henrik Ullum
A1 Søren Brunak
A1 Niels Tommerup
A1 Bjarke Feenstra
A1 Frank Geller
A1 Sisse Rye Ostrowski
A1 Kirsten Grønbæk
A1 Claus Henrik Nielsen
A1 Susanne Dam Nielsen
A1 Ulla Feldt-Rasmussen
YR 2021
UL http://medrxiv.org/content/early/2021/01/25/2021.01.22.21249945.abstract
AB Background Reports of persistent symptoms after hospitalization with COVID-19 have raised concern of a “long COVID” syndrome. This study aimed at characterizing acute and persistent symptoms in non- hospitalized patients with polymerase chain reaction (PCR) confirmed COVID-19.Methods Cohort study of 445 non-hospitalized participants identified via the Danish Civil Registration System with a SARS-CoV-2-positive PCR-test and available biobank samples for genetic analyses. Participants received a digital questionnaire on demographics and COVID-19-related symptoms. Persistent symptoms: symptoms >four weeks (in sensitivity analyses >12 weeks).Results 445 participants were included, of whom 34% were asymptomatic. Most common acute symptoms were fatigue, headache, and sneezing, while fatigue and reduced smell and taste were reported as most severe. Persistent symptoms, most commonly fatigue and memory and concentration difficulties, were reported by 36% of 198 symptomatic participants with follow-up >four weeks. Risk factors for persistent symptoms included female sex (women 44% vs. men 24%, odds ratio 2.7, 95%CI:1.4-5.1, p=0.003) and BMI (odds ratio 1.1, 95%CI:1.0-1.2, p=0.001).Conclusion Among non-hospitalized PCR-confirmed COVID-19 patients one third were asymptomatic while one third of symptomatic participants had persistent symptoms illustrating the heterogeneity of disease presentation. These findings should be considered in future health care planning and policy making related to COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWork related to the present study was supported by a grant from Sygesikring Danmark (2020-0178) to the Danish COVID-19 Genetic Consortium and by the Independent Research Fund Denmark (0216-00014B to NT). KB, LC, DW, MS and SB (Brunak) acknowledge the Novo Nordisk Foundation (grants NNF17OC0027594 and NNF14CC0001). KG was supported by a grant from the European Hematology Association. SDN received research grants from Novo Nordic Foundation, FSS, Lundbeck Foundation, and Rigshospitalet Research Council. UFRs research salary was supported by a research grant from The Kirsten and Freddy Johansens Fund. The funding sources had no impact on the planning or conduction of the study or of any work related to this manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was part of the Epidemiology and Genetics of COVID-19 study approved by the National Committee on Health Research Ethics (ID: NVK 2003947) and by the Data Protection Agency (ID: P-2020-356).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available from The Danish COVID-19 Genetic Consortium but restrictions apply to the availability of data used under license for the current study, and thus are not publicly available. Data are however available from the authors upon reasonable request and with permission from The Danish COVID-19 Genetic Consortium under Danish legislation.